CORVUS PHARMACEUTICALS, INC. (NASDAQ:CRVS) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement.

On May 1, 2017, the Company entered into a clinical trial collaboration agreement with Genentech to evaluate CPI-444 combined with Genentech’s cancer immunotherapy, Tecentriq® (atezolizumab), a monoclonal antibody targeting PD-L1. This Phase 1b/2 clinical trial will evaluate the combination as a second-line therapy in non-small cell lung cancer patients who are resistant/refractory to prior therapy with an anti-PD-(L)1 antibody. to this agreement, the Company will retain global development and commercialization rights to CPI-444. Under the terms of the collaboration agreement, Genentech will manage study operations for the Phase 1b/2 trial, which is expected to begin enrolling patients in the second half of 2017. The Company and Genentech each have the right to terminate the agreement for material breach by the other party. In addition, the agreement may be terminated by either party due to safety considerations, if directed by a regulatory authority or if development of CPI-444 or Tecentriq (atezolizumab) is discontinued. Genentech may elect to terminate the agreement if the Company fails a good manufacturing practices or good distribution practices audit performed by Genentech. Furthermore, the agreement will expire after the first to occur of a set period of time or following the provision by Genentech of the final clinical study report to the Company.

The foregoing summary of the material terms and conditions of the agreement is qualified in its entirety by the actual agreement, which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter and six months ending June 30, 2017 and is incorporated by reference herein.

A copy of the Company’s related press release announcing the transactions is attached hereto as Exhibit 99.1.

Tecentriq® is a registered trademark of Genentech.

Item 9.01. Financial Statements and Exhibits.

Reference is made to the Exhibit Index attached hereto.

About CORVUS PHARMACEUTICALS, INC. (NASDAQ:CRVS)

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. The Company’s lead product candidate, CPI-444, is an oral, small molecule antagonist of the A2A receptor for adenosine, an immune checkpoint. Its other products include adenosine production inhibitor (a monoclonal anti-CD73 antibody); adenosine A2B antagonist, and interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. As of September 30, 2016, the Company had not generated any revenue.

CORVUS PHARMACEUTICALS, INC. (NASDAQ:CRVS) Recent Trading Information

CORVUS PHARMACEUTICALS, INC. (NASDAQ:CRVS) closed its last trading session 00.00 at 9.64 with 182,682 shares trading hands.